The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis Patients Receiving Abrocitinib

What this Trial Is About

Researchers are evaluating real-world treatment patterns and clinical outcomes in patients aged 12 years and older with moderate-to-severe atopic dermatitis who are receiving abrocitinib. The study aims to describe patient demographics and baseline characteristics over a 12-month observation period to better understand how abrocitinib is used in usual clinical practice conditions. Participants will be newly prescribed abrocitinib as decided by their physician during routine care. The study does not involve experimental treatments but observes how abrocitinib is used and its effects in everyday settings. There are no comparator groups or placebo treatments since this is an observational study. During the 12-month observation, researchers will track improvements in eczema severity using measures like the Eczema Area and Severity Index EASI, Investigators Global Assessment IGA, and patient-reported outcomes such as the Peak Pruritus Numerical Rating Scale PP-NRS. Data on treatment duration, quality of life, and symptom changes will also be collected. Patients progress will be monitored at multiple time points including weeks 2, 4, 12, 16, 24, and 52.

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)